Baxter International Inc vs iShares Silver Trust — how do they compare? Baxter International Inc trades at $21.78 (market cap $11.26B), while iShares Silver Trust trades at $52.35. The key difference: Baxter International Inc pays a 0.92% dividend while iShares Silver Trust pays none, and Baxter International Inc is trading nearer its 52-week high, iShares Silver Trust nearer its low. Which is the better fit depends on your goals.
| BAX | SLV | |
|---|---|---|
Market Cap | $11.26B | — |
Sector | Health | — |
52-Week High | $29.22 | $105.57 |
52-Week Low | $15.80 | $33.32 |
Enterprise Value | $18.93B | — |
Dividend Yield | 0.92% | — |
Signals from Pluang's Aura AI — not financial advice
Baxter International (BAX) trades at $22.57, down 0.22% on the day, with mixed technical signals showing a bullish moving average trend but neutral oscillators. The company reported Q1 2026 earnings beat with $0.36 EPS versus $0.31 expected, though net income margin remains negative at -9.7%. Recent news highlights upcoming Q2 earnings call and sustainability initiatives, while analyst consensus sits at $22.67 price target with 42% buy ratings.
BAX faces fundamental challenges with negative profitability metrics and volatile cash flow, but valuation appears reasonable with P/S of 1.02. The stock offers potential upside to analyst targets if operational improvements materialize, though investors must weigh high debt levels and inconsistent earnings performance against turnaround prospects in the medical technology sector.
SLV (iShares Silver Trust) is trading at $52.16, down 3.32% amid broader precious metals weakness. The ETF shows bearish technical signals with moving averages and ADX indicators pointing lower, though RSI readings suggest potential oversold conditions. Recent news highlights silver's dual role as both industrial metal and store of value, with prices down 17.8% year-to-date according to Barron's (July 13, 2026).
Silver's outlook remains challenged by inflation fears and Fed policy uncertainty, though some analysts see potential for recovery to $55-60 range (StoneX Q3 Outlook, July 10, 2026). Key risks include dollar strength, industrial demand fluctuations, and ongoing geopolitical tensions affecting precious metals markets.
Trailing returns across standard periods
Latest headlines on both assets
Baxter offers a variety of medical instruments and supplies to caregivers. It enhanced its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021. Legacy Baxter offers tools to help patients with acute and chronic kidney failure. It also sells a variety of injectable therapies for use in care settings, such as IV pumps, and administrative sets.
Read more on BAX →The ETF seeks to reflect such performance before payment of the ETF's expenses and liabilities. It is not actively managed. The ETF does not engage in any activities designed to obtain a profit from, or to ameliorate losses caused by, changes in the price of silver.
Read more on SLV →